Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MWX203 S4
- Development stage
- Unknown
- Lead developer
- Shanghai Minwei Biotechnology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
MWX203 (including its variant MWX203 S4) is an investigational small interfering RNA (siRNA) therapeutic developed by Shanghai Minwei Biotechnology Co., Ltd., a subsidiary of Lepu Medical. It is designed to target angiopoietin-like protein 3 (ANGPTL3) for the treatment of dyslipidemia, hyperlipidemia, and mixed dyslipidemia. By utilizing RNA interference (RNAi) to silence the expression of ANGPTL3 in the liver, MWX203 aims to lower blood lipid levels, including triglycerides and cholesterol. The drug is administered via subcutaneous injection and has progressed to Phase II clinical trials in China, where it is being evaluated both as a monotherapy and in combination with other lipid-lowering therapies like inclisiran.
- Other names
- MWX203 InjectionMWX-203 InjectionMWX 203 Injection
02
Targets
ANGPTL3 (Angiopoietin-like protein 3)
Beyond the preview
Go deeper on MWX203 S4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MWX203 S4.